Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 ...

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died ...

The two trading partners documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, auto ...

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

A new wave of Alzheimer’s research suggests semaglutide, widely known for diabetes and weight loss, could also slow cognitive ...

RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.

The FDA clearance sets Novo’s medicine up for a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

The drug, which functions similar to psilocybin, scored positive enough results in a mid-stage study that Reunion is now ...